The combined BARD1-CA125 OC test, however, as shown with the BARD1 261-CA125 model, would show high sensitivity and specificity (AUC 0.97) for OC regardless of disease stage, menopausal status, or mutations in breast/ovarian cancer predisposition genes. The gene discussed is MUC16; the disease is ovarian cancer.